Fish oil in XXXX with @entity6 .

@entity1 @entity2298 @entity6 @entity1674 @entity6308 @entity412 @entity413 @entity65 @entity165
BACKGROUND: @entity1 with @entity6 are at increased risk from @entity65 . Dietary fish oils are known to reduce @entity412 levels, but their impact on @entity165 levels, glycemic control and vascular outcomes are not well known. OBJECTIVES: To determine the effects of fish oil supplementation on cardiovascular outcomes, @entity165 levels and glycemic control in @entity1 with @entity6 . SEARCH STRATEGY: We carried out a comprehensive search of the Cochrane Controlled Trials Register, Medline, Embase, Lilacs, bibliographies of relevant papers and contacted experts for identifying additional trials. Date of last search: September 2000. SELECTION CRITERIA: All randomized placebo-controlled trials in which fish oil supplementation was the only intervention in @entity1 with type 2 @entity6 were included. Authors were contacted for missing information. DATA COLLECTION AND ANALYSIS: Three investigators performed data extraction and quality scoring independently with discrepancies resolved by consensus. MAIN RESULTS: Eighteen trials including 823 @entity1 followed for a mean of 12 weeks were included. Doses of fish oil used ranged from 3 to 18 g/day. No trials with vascular event or mortality endpoints were identified. The outcomes studied were glycemic control and lipid levels. Meta-analysis of pooled data demonstrated a statistically significant effect of fish oil in lowering @entity1674 by 0.56 mmol/l (95% CI -0.71 to -0.40 mmol/l) and raising LDL @entity165 by 0.21 mmol/l (95% CI 0.02 to 0.41 mmol/l). No statistically significant effect was observed for fasting @entity413 , HbA1c, total or HDL @entity165 . The @entity412 lowering effect and the elevation in LDL @entity165 were most marked in those trials that recruited @entity1 with @entity2298 and used higher doses of fish oil. No adverse effects of the intervention were reported. REVIEWER'S CONCLUSIONS: Fish oil supplementation in type 2 @entity6 lowers @entity1674 , may raise LDL @entity165 (especially in @entity6308 @entity1 on higher doses of fish oil) and has no statistically significant effect on glycemic control. Trials with vascular event or mortality defined endpoints are needed.
